BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Keeffe EB, Rossignol JF. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J Gastroenterol 2009; 15(15): 1805-1808 [PMID: 19370775 DOI: 10.3748/wjg.15.1805]
URL: https://www.wjgnet.com/1007-9327/full/v15/i15/1805.htm
Number Citing Articles
1
Raúl Romero-Cabello, Raúl Romero-Feregrino, Rodrigo Romero-Feregrino, Octavio Amancio Chassin. Uso de nitazoxanida en infecciones viralesRevista Latinoamericana de Infectología Pediátrica 2021; 34(2): 94 doi: 10.35366/100548
2
Ester Lopez-Suñé, Montse Tuset, Montse Laguno, Asunción Moreno, José M. Miró. Características de los fármacos antivíricos activos frente al virus de la hepatitis y el virus de la influenza: actualización 2009Enfermedades Infecciosas y Microbiología Clínica 2010; 28(4): 253.e1 doi: 10.1016/j.eimc.2010.02.001
3
Daniel Grimm, Robert Thimme, Hubert E. Blum. HBV life cycle and novel drug targetsHepatology International 2011; 5(2): 644 doi: 10.1007/s12072-011-9261-3
4
Mahmoud Saleh, Yaser A. Mostafa, Jyothi Kumari, Momen M. Thabet, Dharmarajan Sriram, Mahmoud Kandeel, Hajjaj H. M. Abdu-Allah. New nitazoxanide derivatives: design, synthesis, biological evaluation, and molecular docking studies as antibacterial and antimycobacterial agentsRSC Medicinal Chemistry 2023; 14(12): 2714 doi: 10.1039/D3MD00449J
5
Flavia P. Bruno, Mino R. Caira, Gustavo A. Monti, Diego E. Kassuha, Norma R. Sperandeo. Spectroscopic, thermal and X-ray structural study of the antiparasitic and antiviral drug nitazoxanideJournal of Molecular Structure 2010; 984(1-3): 51 doi: 10.1016/j.molstruc.2010.09.006
6
Siyu Xu, Naomichi Yamamoto. Anti-infective nitazoxanide disrupts transcription of ribosome biogenesis-related genes in yeastGenes & Genomics 2020; 42(8): 915 doi: 10.1007/s13258-020-00958-0
7
Ana Clara M. Oliveira, Eduardo M. Richter, Thiago R.L.C. Paixão, Diele A.G. Araújo, Rodrigo A.A. Muñoz. Electrochemical determination of nitazoxanide in environmental and pharmaceutical samples using a boron-doped diamond electrodeMicrochemical Journal 2024; 207: 112162 doi: 10.1016/j.microc.2024.112162
8
Danish M. Siddiq, Hoonmo L. Koo, Javier A. Adachi, George M. Viola. Norovirus gastroenteritis successfully treated with nitazoxanideJournal of Infection 2011; 63(5): 394 doi: 10.1016/j.jinf.2011.08.002
9
Na Liu, Fabao Zhao, Haiyong Jia, Diwakar Rai, Peng Zhan, Xuemei Jiang, Xinyong Liu. Non-nucleoside anti-HBV agents: advances in structural optimization and mechanism of action investigationsMedChemComm 2015; 6(4): 521 doi: 10.1039/C4MD00521J
10
Luiz Pedro S. de Carvalho, Gang Lin, Xiuju Jiang, Carl Nathan. Nitazoxanide Kills Replicating and Nonreplicating Mycobacterium tuberculosis and Evades ResistanceJournal of Medicinal Chemistry 2009; 52(19): 5789 doi: 10.1021/jm9010719
11
Stevan A Gonzalez, Emmet B Keeffe. Chronic Hepatitis B and C: Update on TherapyFuture Virology 2009; 4(5): 437 doi: 10.2217/fvl.09.43
12
Abd-Elgawad Radi, Hossam M. Nassef, Abd-Elrahman El-Naggar. Electrochemical and spectral characterization of the host-guest inclusion complex of the antiparasitic drug nitazoxanide with β-cyclodextrinMonatshefte für Chemie - Chemical Monthly 2014; 145(3): 421 doi: 10.1007/s00706-013-1109-1
13
Frederic Vigant, Nuno C. Santos, Benhur Lee. Broad-spectrum antivirals against viral fusionNature Reviews Microbiology 2015; 13(7): 426 doi: 10.1038/nrmicro3475
14
Joao M. Serigado, Manhal Izzy, Harmit Kalia. Novel therapies and potential therapeutic targets in the management of chronic hepatitis BEuropean Journal of Gastroenterology & Hepatology 2017; 29(9): 987 doi: 10.1097/MEG.0000000000000911
15
Latavia Singh, Sunaina Indermun, Mershen Govender, Pradeep Kumar, Lisa C. Du Toit, Yahya E. Choonara, Viness Pillay. Drug Delivery Strategies for Antivirals against Hepatitis B VirusViruses 2018; 10(5): 267 doi: 10.3390/v10050267
16
R. F. Schinazi, L. Bassit, C. Gavegnano. HCV drug discovery aimed at viral eradicationJournal of Viral Hepatitis 2010; 17(2): 77 doi: 10.1111/j.1365-2893.2009.01246.x
17
Khaled Mosaad Elhusseiny, Fatma Abd-Elshahed Abd-Elhay, Mohamed Gomaa Kamel. Possible therapeutic agents for COVID-19: a comprehensive reviewExpert Review of Anti-infective Therapy 2020; 18(10): 1005 doi: 10.1080/14787210.2020.1782742
18
Masahito Minami. Future therapy for hepatitis B virus infectionClinical Journal of Gastroenterology 2015; 8(4): 167 doi: 10.1007/s12328-015-0590-y
19
Abd-Elgawad Radi, Nadia Abd El-Ghany, Tarek Wahdan. Anodic voltammetric methods for determination of the antiparasitic drug nitazoxanide in bulk form, pharmaceutical formulation, and its metabolite tizoxanide in human serumMonatshefte für Chemie - Chemical Monthly 2012; 143(5): 697 doi: 10.1007/s00706-011-0636-x
20
Mohammad Rashidul Hashan, Khaled Mosaad Elhusseiny, Le Huu-Hoai, Thuan Minh Tieu, Soon Khai Low, Le Huu Nhat Minh, Thai Le Ba Nghia, Le Quang Loc, Mai Nhu Y, Peter Samuel Eid, Mohammed Abed, Salma Said Elkolaly, Gehad Mohamed Tawfik, Nguyen Tien Huy. Effect of nitazoxanide on diarrhea: A systematic review and network meta-analysis of randomized controlled trialsActa Tropica 2020; 210: 105603 doi: 10.1016/j.actatropica.2020.105603
21
Wosen Aman, Shaymaa Mousa, Gamal Shiha, Shaker A Mousa. Current status and future directions in the management of chronic hepatitis CVirology Journal 2012; 9(1) doi: 10.1186/1743-422X-9-57
22
Brenda C. Félix-Sonda, Jesús Rivera-Islas, Dea Herrera-Ruiz, Hugo Morales-Rojas, Herbert Höpfl. Nitazoxanide Cocrystals in Combination with Succinic, Glutaric, and 2,5-Dihydroxybenzoic AcidCrystal Growth & Design 2014; 14(3): 1086 doi: 10.1021/cg4015916
23
Meng-Che Lu, Sheng-Chieh Lin, Yi-Hsiang Hsu, Shih-Yen Chen. Epidemiology, Clinical Features, and Unusual Complications of Norovirus Infection in Taiwan: What We Know after Rotavirus VaccinesPathogens 2022; 11(4): 451 doi: 10.3390/pathogens11040451
24
Divya Samantha Kondapi, Sasirekha Ramani, Mary K Estes, Robert L Atmar, Pablo C Okhuysen. Norovirus in Cancer Patients: A ReviewOpen Forum Infectious Diseases 2021; 8(6) doi: 10.1093/ofid/ofab126
25
Ludmila Perelygina, Timo Hautala, Mikko Seppänen, Adebola Adebayo, Kathleen E. Sullivan, Joseph Icenogle. Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiencyAntiviral Research 2017; 147: 58 doi: 10.1016/j.antiviral.2017.09.019
26
Noha Ghusson, Gustavo Vasquez. Successfully Treated Norovirus- and Sapovirus-Associated Diarrhea in Three Renal Transplant PatientsCase Reports in Infectious Diseases 2018; 2018: 1 doi: 10.1155/2018/6846873
27
Simone I. Strasser. Drugs in Development for the Treatment of Chronic Hepatitis BCurrent Hepatitis Reports 2012; 11(2): 111 doi: 10.1007/s11901-012-0131-9
28
Yameng Pei, Chunting Wang, S. Frank Yan, Gang Liu. Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus InfectionJournal of Medicinal Chemistry 2017; 60(15): 6461 doi: 10.1021/acs.jmedchem.6b01442
29
Hongzhuan Zhou, Xia Su, Lulu Lin, Jin Zhang, Qi Qi, Fangfang Guo, Fuzhou Xu, Bing Yang. Inhibitory Effects of Antiviral Drug Candidates on Canine Parvovirus in F81 cellsViruses 2019; 11(8): 742 doi: 10.3390/v11080742
30
Andrew V. Stachulski, Joshua Taujanskas, Sophie L. Pate, Rajith K. R. Rajoli, Ghaith Aljayyoussi, Shaun H. Pennington, Stephen A. Ward, Weiqian David Hong, Giancarlo A. Biagini, Andrew Owen, Gemma L. Nixon, Suet C. Leung, Paul M. O’Neill. Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?ACS Infectious Diseases 2021; 7(6): 1317 doi: 10.1021/acsinfecdis.0c00478
31
María L. Cuestas, Verónica L. Mathet, José R. Oubiña, Alejandro Sosnik. Drug Delivery Systems and Liver Targeting for the Improved Pharmacotherapy of the Hepatitis B Virus (HBV) InfectionPharmaceutical Research 2010; 27(7): 1184 doi: 10.1007/s11095-010-0112-z
32
Laura V. Ashton, Robert L. Callan, Sangeeta Rao, Gabriele A. Landolt. In VitroSusceptibility of Canine Influenza A (H3N8) Virus to Nitazoxanide and TizoxanideVeterinary Medicine International 2010; 2010: 1 doi: 10.4061/2010/891010
33
Michael A. Gelman, Jeffrey S. Glenn. Mixing the right hepatitis C inhibitor cocktailTrends in Molecular Medicine 2011; 17(1): 34 doi: 10.1016/j.molmed.2010.10.005
34
Jianzhong Cao, J. Craig Forrest, Xuming Zhang. A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugsAntiviral Research 2015; 114: 1 doi: 10.1016/j.antiviral.2014.11.010
35
Pasquale Pagliano, Giuliana Scarpati, Carmine Sellitto, Valeria Conti, Anna Maria Spera, Tiziana Ascione, Ornella Piazza, Amelia Filippelli. Experimental Pharmacotherapy for COVID-19: The Latest AdvancesJournal of Experimental Pharmacology 2021; : 1 doi: 10.2147/JEP.S255209
36
Z. M. Zhu, W. J. Zhang. Spectroscopic Analysis of the Interaction Between the Antiparasitic Drug Nitazoxanide and Bovine Serum AlbuminIranian Journal of Science and Technology, Transactions A: Science 2021; 45(3): 867 doi: 10.1007/s40995-021-01102-7